Group One Trading’s Adamas Pharmaceuticals ADMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-3,000
Closed -$15K 9188
2021
Q3
$15K Buy
+3,000
New +$14.6K ﹤0.01% 7331
2021
Q2
Sell
-600
Closed -$3K 8791
2021
Q1
$3K Buy
+600
New +$3.13K ﹤0.01% 7361
2020
Q1
Sell
-11,000
Closed -$42K 5979
2019
Q4
$42K Buy
11,000
+900
+9% +$4.31K ﹤0.01% 4088
2019
Q3
$52K Hold
10,100
﹤0.01% 3954
2019
Q2
$63K Buy
10,100
+10,000
+10,000% +$57.5K ﹤0.01% 3651
2019
Q1
$1K Sell
100
-20,400
-100% -$183K ﹤0.01% 4694
2018
Q4
$175K Sell
20,500
-6,500
-24% -$84.5K ﹤0.01% 2789
2018
Q3
$541K Sell
27,000
-3,300
-11% -$77.5K ﹤0.01% 2213
2018
Q2
$783K Sell
30,300
-9,500
-24% -$263K 0.01% 1932
2018
Q1
$951K Buy
39,800
+15,100
+61% +$476K 0.01% 1561
2017
Q4
$837K Sell
24,700
-58,200
-70% -$1.63M 0.01% 1860
2017
Q3
$1.75M Buy
82,900
+77,300
+1,380% +$1.42M 0.02% 1144
2017
Q2
$98K Buy
5,600
+5,400
+2,700% +$89.3K ﹤0.01% 3122
2017
Q1
$4K Buy
+200
New +$3.41K ﹤0.01% 4360
2016
Q4
Sell
-100
Closed -$2K 4997
2016
Q3
$2K Buy
+100
New +$1.52K ﹤0.01% 4396
2016
Q1
Sell
-1,500
Closed -$42K 5129
2015
Q4
$42K Buy
+1,500
New +$25.3K ﹤0.01% 3514

Group One Trading's ADMS Position: Q4 2021 in Review

Group One Trading sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 16,483 shares — an estimated $81K sold.

Group One Trading first reported a position in ADMS in Q4 2015 and held it in 13 quarters. The position peaked at $794K in Q3 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

  • Group One Trading reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Group One Trading sold 16,483 Adamas Pharmaceuticals shares in Q4 2021, an estimated $81K.
  • Group One Trading first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Group One Trading's Adamas Pharmaceuticals position peaked at $794K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Group One Trading's 13F filing for Q4 2021, filed 11 Feb 2022.